| Literature DB >> 34228177 |
Cinzia Monaco1, Antonio Sorgente1, Robbert Ramak1, Gian Battista Chierchia1, Mark La Meir2, Carlo de Asmundis3.
Abstract
Achieving the goal management of some arrhythmic syndromes can be challenging; medical treatment for inappropriate sinus tachycardia (IST) and postural orthostatic tachycardia syndrome (POTS) may be ineffective, necessitating multidisciplinary team treatment. Implantable defibrillator devices (ICDs), along with anti-arrhythmic drugs (AADs), remain the first-line treatment for primary electrical diseases that pose a risk of sudden cardiac death (SCD). Ablation of the arrhythmogenic substrate is not always suggested in patients with these pathologies, but it may be a valuable support for reducing arrhythmic burden, improving quality of life, and treating pathologies that are resistant to pharmacological treatment; however, this option is not often considered due to the potential risks associated with an invasive approach. Minimally invasive hybrid ablation in these syndromes, such as a hybrid thoracoscopic approach and the use of non-invasive mapping systems, reduces post-surgery complications and ensures the best possible outcome for the patient.Entities:
Keywords: Arrhythmogenic substrate ablation; Electrocardiographic mapping; IST; POTS; Thoracoscopic hybrid ablation
Year: 2021 PMID: 34228177 DOI: 10.1007/s00399-021-00778-z
Source DB: PubMed Journal: Herzschrittmacherther Elektrophysiol ISSN: 0938-7412